AGRX Fails To SECURE Investor Confidence, ITEK Hit Hard, CBAY …

Shutterstock photo

(RTTNews.com) – Shares of Agile Therapeutics Inc. ( AGRX ) got pounded in extended trading on Tuesday despite positive results from SECURE, the company’s phase III trial of its once-weekly contraceptive patch Twirla.

SECURE was conducted to address issues raised by the FDA in its 2013 Complete Response Letter to the company.

In the SECURE trial, the PEARL-index score of Twirla was 4.80 in subjects 35 years of age and under. The Pearl Index is the number of failures that will occur among 100 women using a contraceptive method for a year.

However, Johnson Johnson discontinued the production of that birth control patch when Mylan was granted FDA approval in April 2014 to market a generic version

... read more at: http://www.nasdaq.com/article/agrx-fails-to-secure-investor-confidence-itek-hit-hard-cbay-rises-on-kowa-deal-20170104-00025

by

AGRX Fails To SECURE Investor Confidence, ITEK Hit Hard, CBAY …

Shutterstock photo

(RTTNews.com) – Shares of Agile Therapeutics Inc. ( AGRX ) got pounded in extended trading on Tuesday despite positive results from SECURE, the company’s phase III trial of its once-weekly contraceptive patch Twirla.

SECURE was conducted to address issues raised by the FDA in its 2013 Complete Response Letter to the company.

In the SECURE trial, the PEARL-index score of Twirla was 4.80 in subjects 35 years of age and under. The Pearl Index is the number of failures that will occur among 100 women using a contraceptive method for a year.

However, Johnson Johnson discontinued the production of that birth control patch when Mylan was granted FDA approval in April 2014 to market a generic version

... read more at: http://www.nasdaq.com/article/agrx-fails-to-secure-investor-confidence-itek-hit-hard-cbay-rises-on-kowa-deal-20170104-00025

by